Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 14/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924609 | 0.96 | KIF11 (0.48) | KIF11OPRM1MEN1KMT2A | |
| SCHEMBL6930767 | 0.91 | OPRM1 (0.41) | KIF11OPRM1 | |
| SCHEMBL6928024 | 0.88 | DRD2 (0.42) | KIF11OPRM1MEN1KMT2A | |
| SCHEMBL6930283 | 0.84 | KIF11 (0.36) | KIF11OPRM1 | |
| SCHEMBL6926610 | 0.84 | KIF11 (0.42) | KIF11OPRM1 | |
| SCHEMBL6930222 | 0.84 | KIF11 (0.36) | KIF11OPRM1 | |
| SCHEMBL6930212 | 0.81 | KCNA5 (0.41) | KIF11OPRM1MEN1KMT2A | |
| SCHEMBL6926714 | 0.79 | CHRM3 (0.35) | KIF11OPRM1MEN1KMT2A | |
| SCHEMBL11483956 | 0.77 | OPRM1 (0.32) | KIF11OPRM1 | |
| SCHEMBL11495005 | 0.76 | OPRM1 (0.31) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019051-A4 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORP (US) | 2003-05-28 | — | — | EP | claimed |
| EP-1119354-A4 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORP (US) | 2003-02-12 | — | — | EP | claimed |
| JP-2002527392-A | — | — | 2002-08-27 | — | — | JP | claimed |
| EP-1119354-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | Adolor Corporation (US) | 2001-08-01 | — | — | EP | claimed |
| JP-2001510157-A | — | — | 2001-07-31 | — | — | JP | claimed |
| EP-1019051-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | Adolor Corporation (US) | 2000-07-19 | — | — | EP | claimed |
| EP-1003489-A1 | FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND METHOD OF TREATING HYPERALGESIC AND PRURITIC CONDITIONS THEREWITH | Adolor Corporation (US) | 2000-05-31 | — | — | EP | claimed |
| WO-2000021530-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORPORATION (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999003472-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | claimed |
| WO-1999003455-A1 | FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND METHOD OF TREATING HYPERALGESIC AND PRURITIC CONDITIONS THEREWITH | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | claimed |
| EP-1019051-A4 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORP (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1119354-A4 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORP (US) | 2003-02-12 | — | — | EP | disclosed |
| EP-1119354-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | Adolor Corporation (US) | 2001-08-01 | — | — | EP | disclosed |
| EP-1019051-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | Adolor Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1003489-A1 | FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND METHOD OF TREATING HYPERALGESIC AND PRURITIC CONDITIONS THEREWITH | Adolor Corporation (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-2000021530-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORPORATION (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999003455-A1 | FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND METHOD OF TREATING HYPERALGESIC AND PRURITIC CONDITIONS THEREWITH | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| WO-1999003472-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |